U.S. markets closed

Bolt Biotherapeutics, Inc. (BOLT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.4700+0.0200 (+1.38%)
At close: 04:00PM EST
1.4606 -0.01 (-0.64%)
After hours: 06:54PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close1.4500
Bid1.4700 x 1200
Ask1.4900 x 1100
Day's Range1.4500 - 1.5100
52 Week Range1.1800 - 3.6400
Avg. Volume297,214
Market Cap55.362M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.6360
Earnings DateNov 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for BOLT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Bolt Biotherapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 07/18/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    7 months agoArgus Research
View more
  • GlobeNewswire

    Bolt Biotherapeutics to Present at February Investor Conferences

    REDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in two upcoming conferences in February: Guggenheim Healthcare Talks 2023 Oncology DayFireside chat on Wednesday, Feb. 8 at 12:55 p.m. PST (3:55 p.m. EST) Virtual SVB Securities Global Biopharma Conference 2023Fireside chat on Thursday, Feb

  • Simply Wall St.

    Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Bolt Biotherapeutics Appoints Laura Berner to Board of Directors

    REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Laura Berner to its Board of Directors effective Dec. 14, 2022. “Laura is an accomplished biopharmaceutical executive with impressive corporate leadership, operations, and business development experience,” said Randall Schatzman, Ph.D., Chief Executive Officer